ValiRx PLC Appointment of Joint Broker (1896T)
13 Noviembre 2019 - 1:01AM
UK Regulatory
TIDMVAL
RNS Number : 1896T
ValiRx PLC
13 November 2019
VALIRX PLC
("ValiRx" or the "Company")
APPOINTMENT OF JOINT BROKER
London, UK., 13 November 2019: ValiRx Plc (AIM: VAL), the
clinical stage biotechnology company, is pleased to announce the
appointment of Allenby Capital Limited as the Company's joint
broker, with immediate effect.
Dr Satu Vainikka, CEO of ValiRx Plc, commented:
"I very much look forward to working with the team at Allenby
Capital and to ValiRx benefiting from the broker's life-science and
healthcare research capabilities to promote and facilitate
understanding and transparency regarding the progress of our
clinical trials".
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray / Jo Turner / Ludovico
Lazzaretti
Allenby Capital Limited (Joint Broker) Tel: +44 (0) 20 3328 5656
Jeremy Porter / Alex Brearley (Corporate
Finance)
Kelly Gardiner (Equity Sales)
Novum Securities Limited (Joint Broker) Tel: +44 (0) 20 7399 9400
Colin Rowbury
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPGGGAWGUPBPGP
(END) Dow Jones Newswires
November 13, 2019 02:01 ET (07:01 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024